當前位置：首頁 SCI期刊 SCIE期刊醫學中科院4區 JCRQ2 期刊介紹(非官網)

Immunopharmacology And ImmunotoxicologySCIE

國際簡稱：IMMUNOPHARM IMMUNOT 參考譯名：免疫藥理學和免疫毒理學

中科院分區
4區
CiteScore分區
Q2
JCR分區
Q2

基本信息：: ISSN：0892-3973; E-ISSN：1532-2513; 是否OA：未開放; 是否預警：否; TOP期刊：否

出版信息：: 出版地區：UNITED STATES; 出版商：Informa Healthcare; 出版語言：English; 出版周期：Quarterly; 出版年份：1987; 研究方向：醫學-毒理學

評價信息：: 影響因子：2.9; H-index：42; CiteScore指數：5.4; SJR指數：0.68; SNIP指數：0.679

發文數據：: Gold OA文章占比：4.26%; 研究類文章占比：86.44%; 年發文量：59; 自引率：0; 開源占比：0.0297; 出版撤稿占比：0.0136...; 出版國人文章占比：0.35; OA被引用占比：0

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數據中科院SCI分區 JCR分區發文數據常見問題

英文簡介Immunopharmacology And Immunotoxicology期刊介紹

The journal Immunopharmacology and Immunotoxicology is devoted to pre-clinical and clinical drug discovery and development targeting the immune system. Research related to the immunoregulatory effects of various compounds, including small-molecule drugs and biologics, on immunocompetent cells and immune responses, as well as the immunotoxicity exerted by xenobiotics and drugs. Only research that describe the mechanisms of specific compounds (not extracts) is of interest to the journal.

The journal will prioritise preclinical and clinical studies on immunotherapy of disorders such as chronic inflammation, allergy, autoimmunity, cancer etc. The effects of small-drugs, vaccines and biologics against central immunological targets as well as cell-based therapy, including dendritic cell therapy, T cell adoptive transfer and stem cell therapy, are topics of particular interest. Publications pointing towards potential new drug targets within the immune system or novel technology for immunopharmacological drug development are also welcome.

With an immunoscience focus on drug development, immunotherapy and toxicology, the journal will cover areas such as infection, allergy, inflammation, tumor immunology, degenerative disorders, immunodeficiencies, neurology, atherosclerosis and more.

Immunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinical cases, on the condition that the results reported are based on original, clinical, or basic research that has not been published elsewhere in any journal in any language (except in abstract form relating to paper communicated to scientific meetings and symposiums).

期刊簡介Immunopharmacology And Immunotoxicology期刊介紹

《Immunopharmacology And Immunotoxicology》自1987出版以來，是一本醫學優秀雜志。致力于發表原創科學研究結果，并為醫學各個領域的原創研究提供一個展示平臺，以促進醫學領域的的進步。該刊鼓勵先進的、清晰的闡述，從廣泛的視角提供當前感興趣的研究主題的新見解，或審查多年來某個重要領域的所有重要發展。該期刊特色在于及時報道醫學領域的最新進展和新發現新突破等。該刊近一年未被列入預警期刊名單，目前已被權威數據庫SCIE收錄，得到了廣泛的認可。

該期刊投稿重要關注點：

預計審稿時間：偏慢,4-8周
醫學
TOXICOLOGY
SCIE
中科院4區
非預警

Cite Score數據（2024年最新版）Immunopharmacology And Immunotoxicology Cite Score數據

CiteScore：5.4
SJR：0.68
SNIP：0.679

學科類別	分區	排名	百分位
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Toxicology	Q2	58 / 133	56%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Pharmacology	Q2	141 / 313	55%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Immunology and Allergy	Q2	115 / 233	50%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Immunology	Q3	133 / 236	43%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評價期刊影響力的文獻計量指標。反映出一家期刊近期發表論文的年篇均引用次數。CiteScore以Scopus數據庫中收集的引文為基礎，針對的是前四年發表的論文的引文。CiteScore的意義在于，它可以為學術界提供一種新的、更全面、更客觀地評價期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標來評價。

歷年Cite Score趨勢圖

中科院SCI分區Immunopharmacology And Immunotoxicology 中科院分區

中科院 2023年12月升級版 綜述期刊：否 Top期刊：否

大類學科	分區	小類學科	分區
醫學	4區	TOXICOLOGY 毒理學 IMMUNOLOGY 免疫學 PHARMACOLOGY & PHARMACY 藥學	3區 4區 4區

中科院分區表 是以客觀數據為基礎，運用科學計量學方法對國際、國內學術期刊依據影響力進行等級劃分的期刊評價標準。它為我國科研、教育機構的管理人員、科研工作者提供了一份評價國際學術期刊影響力的參考數據，得到了全國各地高校、科研機構的廣泛認可。

中科院分區表 將所有期刊按照一定指標劃分為1區、2區、3區、4區四個層次，類似于“優、良、及格”等。最開始，這個分區只是為了方便圖書管理及圖書情報領域的研究和期刊評估。之后中科院分區逐步發展成為了一種評價學術期刊質量的重要工具。

歷年中科院分區趨勢圖

JCR分區Immunopharmacology And Immunotoxicology JCR分區

2023-2024 年最新版

按JIF指標學科分區	收錄子集	分區	排名	百分位
學科：IMMUNOLOGY	SCIE	Q3	108 / 181	40.6%
學科：PHARMACOLOGY & PHARMACY	SCIE	Q2	147 / 354	58.6%
學科：TOXICOLOGY	SCIE	Q2	49 / 106	54.2%

按JCI指標學科分區	收錄子集	分區	排名	百分位
學科：IMMUNOLOGY	SCIE	Q2	85 / 181	53.31%
學科：PHARMACOLOGY & PHARMACY	SCIE	Q2	162 / 354	54.38%
學科：TOXICOLOGY	SCIE	Q2	53 / 106	50.47%

JCR分區的優勢在于它可以幫助讀者對學術文獻質量進行評估。不同學科的文章引用量可能存在較大的差異，此時單獨依靠影響因子(IF)評價期刊的質量可能是存在一定問題的。因此，JCR將期刊按照學科門類和影響因子分為不同的分區，這樣讀者可以根據自己的研究領域和需求選擇合適的期刊。

歷年影響因子趨勢圖

發文數據

2023-2024 年國家/地區發文量統計

國家/地區數量
CHINA MAINLAND87
Iran39
India20
South Korea13
USA12
Brazil10
Turkey9
Egypt8
Japan7
Taiwan5

本刊中國學者近年發表論文

1、Xanthones from securidaca inappendiculata antagonizes the anti-rheumatic effect of methotrexate by inhibiting reduced folate carrier 1
Author: Zhang, Sa-sa; Wu, Yi-jin; Pan, Shu; Wang, Qi-hai; Chen, Wen-gang; Wang, Zhong-fang; Xu, Jin-ying; Zuo, Jian; Yin, Qin

Journal: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. 2023; Vol. 45, Issue 1, pp. 16-25. DOI: 10.1080/08923973.2022.2103707
2、A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Author: Liu, Tong; Jiang, Shuai; Teng, Xue; Zhong, Lu; Liu, Mengmeng; Jin, Yao; Dong, Mei

Journal: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. 2023; Vol. 45, Issue 1, pp. 1-9. DOI: 10.1080/08923973.2022.2112222
3、Corynoline ameliorates dextran sulfate sodium-induced colitis in mice by modulating Nrf2/NF-kappa B pathway
Author: Zhang, Haihua; Lang, Wuying; Li, Sufen; Xu, Chao; Wang, Xiumin; Li, Yunyu; Zhang, Zhiqiang; Wu, Tonglei; Feng, Minshan

Journal: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. 2023; Vol. 45, Issue 1, pp. 26-34. DOI: 10.1080/08923973.2022.2112218
4、Sulforaphane suppresses skin squamous cell carcinoma cells proliferation through miR-199a-5p/Sirt1/CD44ICD signaling pathway
Author: Zhang, Yang; Ai, Ping; Chen, Shang-zhou; Lei, Shu-ying

Journal: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. 2023; Vol. 45, Issue 1, pp. 52-60. DOI: 10.1080/08923973.2022.2112221
5、Monensin synergizes with chemotherapy in uveal melanoma through suppressing RhoA
Author: Zeng, Chaoxia; Long, Mingxia; Lu, Ying

Journal: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. 2023; Vol. 45, Issue 1, pp. 35-42. DOI: 10.1080/08923973.2022.2112219
6、alpha-Cyperone ameliorates depression in mammary gland hyperplasia and chronic unpredictable mild stress rat by regulating hormone, inflammation, and oxidative stress
Author: Qiao, Nan; Wang, Qinnan; Tao, Ye; Wu, Jinna; Fang, Yong; Ni, Yusheng; Ding, Xiaowen

Journal: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. 2023; Vol. 45, Issue 1, pp. 73-82. DOI: 10.1080/08923973.2022.2115925
7、Protective effects of Tripterygium glycoside on IL-1 beta-induced inflammation and apoptosis of rat chondrocytes via microRNA-216a-5p/TLR4/NF-kappa B axis
Author: Huang, Zhen; Song, Shuanglin; Zhang, Di; Bian, Zhenyu; Han, Jinsheng

Journal: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. 2023; Vol. 45, Issue 1, pp. 61-72. DOI: 10.1080/08923973.2022.2115924
8、Sestrin2 suppresses ferroptosis to alleviate septic intestinal inflammation and barrier dysfunction
Author: Liu, Wei; Xu, Chanchan; Zou, Zhiqiang; Weng, Qinyong; Xiao, Ying

Journal: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. 2023; Vol. 45, Issue 2, pp. 123-132. DOI: 10.1080/08923973.2022.2121927